Fulcrum Therapeutics (NASDAQ:FULC) Sees Large Volume Increase – Time to Buy?

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) saw unusually-high trading volume on Tuesday . Approximately 2,510,131 shares changed hands during trading, an increase of 150% from the previous session’s volume of 1,002,875 shares.The stock last traded at $7.5480 and had previously closed at $6.58.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Cantor Fitzgerald upped their target price on shares of Fulcrum Therapeutics from $15.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, December 8th. Truist Financial set a $17.00 price objective on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Stifel Nicolaus set a $25.00 target price on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Royal Bank Of Canada lifted their target price on shares of Fulcrum Therapeutics from $7.00 to $10.00 and gave the stock a “sector perform” rating in a research report on Monday, December 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $23.00 price target (up from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Fulcrum Therapeutics Price Performance

The company has a market capitalization of $503.50 million, a PE ratio of -6.42 and a beta of 3.23. The company has a 50-day moving average of $9.13 and a two-hundred day moving average of $9.62.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.31) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.31). As a group, research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Insider Transactions at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, Director Robert J. Gould sold 15,000 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $11.87, for a total transaction of $178,050.00. Following the sale, the director directly owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This trade represents a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.00% of the company’s stock.

Institutional Trading of Fulcrum Therapeutics

Several institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. bought a new position in Fulcrum Therapeutics in the 4th quarter worth approximately $30,000. Meeder Asset Management Inc. bought a new position in shares of Fulcrum Therapeutics during the 4th quarter valued at about $39,000. Quarry LP purchased a new position in shares of Fulcrum Therapeutics during the third quarter valued at about $35,000. Persistent Asset Partners Ltd bought a new position in Fulcrum Therapeutics during the fourth quarter valued at approximately $75,000. Finally, Farther Finance Advisors LLC grew its holdings in Fulcrum Therapeutics by 108.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after buying an additional 3,697 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.